| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 41,961 | 33,062 | 22,117 | 21,711 | 36,012 |
| Sales Growth | +26.92% | +49.49% | +1.87% | -39.71% | -72.14% |
| Net Income | -10,694 | -13,083 | -29,983 | -54,801 | -66,353 |
| Net Income Growth | +18.26% | +56.37% | +45.29% | +17.41% | -4,133.62% |
Medipharm Labs Corp (LABS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.
Fiscal Year End Date: 12/31